Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Soo Yeon Jang x
  • Refine by access: All content x
Clear All Modify Search
Soo Yeon Jang Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

Search for other papers by Soo Yeon Jang in
Google Scholar
PubMed
Close
and
Kyung Mook Choi Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

Search for other papers by Kyung Mook Choi in
Google Scholar
PubMed
Close

Osteosarcopenia, which refers to the concomitant presence of osteoporosis and sarcopenia, is expected to increase in the rapidly progressive aging world, with serious clinical implications. However, the pathophysiology of osteosarcopenia has not been fully elucidated, and no optimal treatment specific to osteosarcopenia is available. The RANKL–RANK pathway is widely used as a therapeutic target for osteoporosis. Growing evidence supports the importance of the RANKL–RANK pathway, not only in bone, but also in muscle, and the therapeutic potential of targeting this pathway in muscle diseases has been noted. The muscles and bones closely communicate with each other through various secretory factors called myokines and osteokines. This review covers the roles of the RANKL–RANK pathway in the bone and muscle and their reciprocal interactions. Moreover, we will suggest future directions to move forward for the treatment of osteosarcopenia to prepare for an upcoming aging society.

Restricted access